The biotechnology bubble machine

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    The Biotech Advisor (Charter Financial Publishing Network, Shrewsbury, NJ, 2002).

  2. 2

    Ackerman, J. A promise unfulfilled in biotechnology: decline and fall of Alpha-Beta speaks volumes about pitballs of industry. The Boston Globe, February 10 (1999).

    Google Scholar 

  3. 3

    Leonhardt, D. Northeast Quietly Becomes a Health Care Corridor. New York Times, December 30 (2002).

  4. 4

    http://www.bio.org/news/stats.asp

  5. 5

    Lähteenmäki, R. & Fletcher, L. Nat. Biotechnol. 21, 551–555 (2002).

    Article  Google Scholar 

  6. 6

    Feldbaum, C.B., Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (E&Y, New York, 2000).

  7. 7

    http://www.bio.org/er/approveddrugs.asp

  8. 8

    Lee, K.L., et al. Ann. Intern. Med. 120, 876–885 (1994).

    CAS  Article  Google Scholar 

  9. 9

    Federal Trade Commission. Resolving Anticompetitive Concerns, FTC Clears $16 Billion Acquisition of Immunex Corp. by Amgen Inc. (FTC, Washington, DC, 2002).

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rasnick, D. The biotechnology bubble machine. Nat Biotechnol 21, 355–356 (2003). https://doi.org/10.1038/nbt0403-355

Download citation

Further reading